The B6 Loophole: How Compounders Are Trying to Stay Legal (And Why the FDA Disagrees)

If you've been prescribed compounded semaglutide in the last year, there's a good chance your vial also contains vitamin B6 (pyridoxine), B12 (cyanocobalamin), niacinamide (B3), or levocarnitine. This isn't random — it's a legal strategy.

The Theory: "It's Not a Copy If It's Personalized"

Under federal law, compounding pharmacies generally cannot make drugs that are "essentially a copy" of commercially available medications. When the FDA declared GLP-1 shortages resolved and enforcement windows closed, compounders needed a legal argument for continued production.

The argument goes like this: if you add an extra ingredient (like B6 or B12) to compounded semaglutide, the resulting formulation is a new, personalized compound — not a copy of Ozempic or Wegovy. Therefore, the "essentially a copy" prohibition doesn't apply.

According to market research firm IQVIA, more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients by October 2025. The additives "may serve as a rationale for continued compounding despite the FDA's resolution of supply shortages," IQVIA researchers noted.

The FDA's Response: It's Still a Copy

The FDA addressed this directly in April 2026 guidance. The agency stated that a compounded semaglutide product combined with B12 will be considered "essentially a copy" of a commercially available drug when:

• The drug products use the same route of administration (e.g., both are injectable)
• The amounts of semaglutide and B12 are within 10% of the strengths of the respective commercially available products

Eli Lilly's Testing: Quality Concerns

Eli Lilly independently tested 10 samples of compounded tirzepatide-B12 products. All 10 contained measurable levels of an impurity created during the compounding process. This data has been cited in both litigation and in the FDA's regulatory record.

What Counts as Legitimate Personalization?

The FDA hasn't banned all patient-specific compounding. Legitimate personalization under 503A might include:

• A documented allergy to an inactive ingredient in the commercial formulation
• A medical condition requiring a dosage form that doesn't exist commercially (though the FDA rejected sublingual and buccal forms as meeting this standard for semaglutide)
• A physician-documented medical necessity that the commercial product cannot address

What does not count: cost savings, insurance coverage gaps, patient preference for a compounding pharmacy, or simply adding a vitamin to the formulation.

The Practical Landscape

Many compounding pharmacies and telehealth platforms continue to operate under the personalization theory. Some have added more exotic ingredients or changed delivery formats (sublingual drops, troches) to create more distance from commercial formulations.

The FDA's enforcement has been escalating but not universal. The agency issued 30 warning letters to telehealth companies in a single day (March 3, 2026) and has referred cases to the DOJ. But thousands of prescriptions continue to be filled.

What Patients Should Do

Ask your provider directly: "Is this compounded formulation legally defensible under current FDA guidance?" A reputable provider will give you an honest answer about the regulatory risk. If they dismiss the question or claim there's "no issue," that's a red flag.

Consider your transition options. With the Wegovy pill at $149/mo, Foundayo at $149/mo, and the Medicare Bridge at $50/mo launching in July, the cost gap that drove patients to compounded options has narrowed significantly.